Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Gassert

Gastroenterology St Augustine, FL Medical Doctor

NPI 1073575403 CMS profile 2889

216 Southpark Cir E, St Augustine, FL 32086

Open in the dashboard

General payments

$8,494

490 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Gassert of St Augustine, FL is reported in the CMS Open Payments database as having received $8,494 across 490 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,377 118
2024 General $1,861 99
2023 General $1,489 90
2022 General $1,217 71
2021 General $799 58
2020 General $257 16
2019 General $494 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Gassert
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Daniel Gassert were reported at $2,377. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Daniel Gassert Gastroenterology median Middle half National median
2019 $494 $417 $126–$1,100 $163
2020 $257 $224 $74–$624 $114
2021 $799 $352 $106–$1,054 $132
2022 $1,217 $448 $129–$1,270 $149
2023 $1,489 $533 $150–$1,390 $160
2024 $1,861 $605 $160–$1,606 $164
2025 $2,377 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,271 146 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $921 54 payments
  3. Janssen Biotech, Inc. $827 46 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $743 44 payments
  5. QOL Medical, LLC $352 15 payments
  6. Regeneron Healthcare Solutions, Inc. $338 12 payments
  7. Madrigal Pharmaceuticals $312 17 payments
  8. Genzyme Corporation $308 14 payments
  9. Gilead Sciences, Inc. $291 20 payments
  10. Merck Sharp & Dohme Corporation $286 18 payments
  11. Other $1,845 104 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,353 487 payments
  2. Education $141 3 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $766 38 payments
  2. XIFAXAN $675 40 payments
  3. ENTYVIO $633 33 payments
  4. STELARA $567 30 payments
  5. SKYRIZI $502 30 payments
  6. CREON $502 40 payments
  7. LINZESS $499 38 payments
  8. HUMIRA $400 27 payments
  9. DUPIXENT $308 14 payments
  10. DIFICID $286 18 payments
  11. Other $4,493 256 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,443

Median for Gastroenterology: 569

Drug cost

$393,771

Median for Gastroenterology: $104,976

Branded share of claims

22.3%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 69 $77,970
Humira(Cf) Pen Adalimumab Brand 11 $74,626
Xeljanz Xr Tofacitinib Citrate Brand 11 $57,807
Creon Lipase/Protease/Amylase Brand 20 $54,979
Viberzi Eluxadoline Brand 22 $43,763
Mesalamine Generic 18 $26,870
Lialda Mesalamine Brand 15 $16,574
Dexlansoprazole Dr Dexlansoprazole Brand 22 $6,288
Omeprazole Generic 278 $5,165
Pantoprazole Sodium Generic 359 $4,936

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$191,200

Of which drugs: $47,508

Medicare patients

699

Average age 74

Services billed

5,154

374 women, 325 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 38%
Diabetes 29%
Chronic kidney disease 28%
Depression 25%
Atrial fibrillation 23%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Infusion, normal saline solution, 250 cc J7050 Office 11 12 $6

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $221
$221 — —
Sucraid
  • QOL Medical, LLC $215
$215 — —
DUPIXENT
  • GENZYME CORPORATION $122
  • Regeneron Healthcare Solutions, Inc. $64
$186 — —
STELARA
  • Janssen Biotech, Inc. $143
$143 — —
RINVOQ
  • AbbVie, Inc. $131
$131 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

490 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record